GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for POISE-3 Pilot

POISE-3 Pilot

Official Title

The PeriOperative ISchemic Evaluation-3 (POISE-3) pilot Trial

Status

Completed

Overview

We want to undertake a large international factorial RCT to establish the effects of rosuvastatin versus placebo and tranexamic acid versus placebo in patients undergoing noncardiac surgery (i.e. the POISE-3 Trial). Prior to undertaking a large international trial, we first need to undertake a pilot to establish the feasibility of such an RCT.

Study Design

Multicentre, blinded, randomized placebo controlled trial of rosuvastatin and tranexamic acid (TXA)

Primary Endpoint

To determine the feasibility and the resource requirements of a trial of rosuvastatin versus placebo and tranexamic acid versus placebo; and to determine the feasibility of administering perioperative rosuvastatin and TXA in patients with, or at risk of, atherosclerotic disease who are undergoing noncardiac surgery.

Number of Patients

100

Number of Sites

2

Number of Countries

1

Study Period

2015-2016

Principal Investigator

PJ Devereaux

Program Manager

Shirley Pettit

Research Coordinator

Kayla Pohl

Follow by Email
LinkedIn
Twitter
FACEBOOK